Tuba Elif ŞENEL
(Sağlık Bilimleri Üniversitesi, Haseki Eğitim ve Araştırma Hastanesi, Nefroloji Kliniği, İstanbul, Türkiye)
Sami UZUN
(Sağlık Bilimleri Üniversitesi, Haseki Eğitim ve Araştırma Hastanesi, Nefroloji Kliniği, İstanbul, Türkiye)
Egemen CEBECİ
(Sağlık Bilimleri Üniversitesi, Haseki Eğitim ve Araştırma Hastanesi, Nefroloji Kliniği, İstanbul, Türkiye)
Oktay ÖZKAN
(Sağlık Bilimleri Üniversitesi, Haseki Eğitim ve Araştırma Hastanesi, Nefroloji Kliniği, İstanbul, Türkiye)
Ahmet BEHLÜL
(Sağlık Bilimleri Üniversitesi, Haseki Eğitim ve Araştırma Hastanesi, Nefroloji Kliniği, İstanbul, Türkiye)
Ayça EROĞLU
(Sağlık Bilimleri Üniversitesi, Haseki Eğitim ve Araştırma Hastanesi, Nefroloji Kliniği, İstanbul, Türkiye)
Yasemin ÖZLÜK
(İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Patoloji Anabilim Dalı, İstanbul, Türkiye)
Savaş ÖZTÜRK
(Sağlık Bilimleri Üniversitesi, Haseki Eğitim ve Araştırma Hastanesi, Nefroloji Kliniği, İstanbul, Türkiye)
Yıl: 2019Cilt: 28Sayı: 1ISSN: 1300-7718 / 2667-4440Sayfa Aralığı: 88 - 90İngilizce

33 0
Case Report of a Patient with Goodpasture’s Syndrome Who Relapsed While on Hemodialysis
Goodpasture’s syndrome is a rare autoimmune disease in which anti-glomerular basement membrane antibodies damage the glomerular and alveolar basement membrane. Its relapse is very rare, compared to other pulmonary-renal syndromes. Herein, we present an unusual case of Goodpasture’s syndrome, which recurred despite immunosuppressive treatment. After the initial treatment with corticosteroid and cyclophosphamide pulses, plasmapheresis, alveolar hemorrhage ended, and the anti-glomerular basement membrane antibody finding became negative, but hemodialysis had to be continued. After 8 months of hemodialysis, anti-glomerular basement membrane antibodies were re-detected, and hemoptysis occurred a month later. Then, plasmapheresis, intravenous immunoglobulin, and methylprednisone were given in addition to azathioprine treatment; however, the serum anti-glomerular basement membrane antibody positivity persisted. Relapse of this syndrome is rare, and if observed, it generally strikes years following disappearance of anti-glomerular basement membrane antibodies; however, in our case, relapse was observed within a few months. It should be kept in mind that, in patients who achieve remission following immunosuppressive therapy, clinical and serological relapses are rare, and the anti-glomerular basement membrane antibody positivity may persist despite the application of immunosuppressive agents in subjects who relapsed.
Dergititle.paper.fact_presentationErişime Açık
  • 1. Dugo M, Pasi A, Gatti PL, Mastrosimone S, Laurino L, Barberio G, et al. [Goodpasture’s disease: a case series]. G Ital Nefrol 2014; 31: pii: gin/31.1.9.
  • 2. Lahmer T, Heemann U. Anti-glomerular basement membrane antibody disease: a rare autoimmune disorder affecting the kidney and the lung. Autoimmun Rev 2012; 12: 169-73. [CrossRef]
  • 3. Tang W, McDonald SP, Hawley CM, Badve SV, Boudville NC, Brown FG, et al. Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. Kidney Int 2013; 83: 503-10. [CrossRef]
  • 4. Boyce NW, Holdsworth SR: Pulmonary manifestations of the clinical syndrome of acute glomerulonephritis and lung hemorrhage. Am J Kidney Dis 1986; 8: 31-6. [CrossRef]
  • 5. Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Pagliuca G, et al. Goodpasture’s syndrome: a clinical update. Autoimmun Rev 2015; 14: 246-53. [CrossRef]
  • 6. Malho A, Santos V, Cabrita A, Silva AP, Pinto I, Bernardo I, et al. Severe Relapsing Goodpasture’s Disease Successfully Treated with Mycophenolate Mofetil. Int J Nephrol 2010; 2010: 383548. [CrossRef]
  • 7. Levy JB, Lachmann RH, Pusey CD. Recurrent Goodpasture’s disease. Am J Kidney Dis 1996; 27: 573-8. [CrossRef]
  • 8. Gu B, Magil AB, Barbour SJ. Frequently relapsing anti-glomerular basement membrane antibody disease with changing clinical phenotype and antibody characteristics over time. Clin Kidney J 2016; 9: 661-4. [CrossRef]
  • 9. Segelmark M, Dahlberg P, Wieslander J. Anti-GBM disease with a mild relapsing course and low levels of anti-GBM autoantibodies. Clin Kidney J 2012; 5: 549-51. [CrossRef]
  • 10. Touzot M, Poisson J, Faguer S, Ribes D, Cohen P, Geffray L, et al. Rituximab in anti-GBM disease: A retrospective study of 8 patients. J Autoimmun 2015; 60: 74-9. [CrossRef]

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.